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All chemicals and reagents were purchased from commercially available sources and used 
without further purification. Moisture-sensitive reactions were conducted under argon with 
oven-dried glassware and anhydrous solvents. Reaction progress was monitored by thin-layer 
chromatography (TLC) using Alugram® SIL G/UV254 pre-coated plates (Macherey-Nagel; 
Düren; Germany). Column flash chromatography was carried out using silica gel 60 (40-64 
µm; Merck; Darmstadt; Germany). Melting points (M. p.) were determined on a Linström 
capillary apparatus (Wagner & Munz GmbH; Vienna; Austria) in open capillary tubes and were 
not corrected. The purity of all the tested compounds was > 95% as determined by LC-MS 
[Dionex Ultimate 3000 system incorporating a LPG-3400SD pump, a WPS-3000 TSL 
autosampler, a TCC-3000SD column compartment, a DAD3000 diode array detector and a 
MSQ 3000 low resolution mass spectrometer (Thermo Fisher Scientific Inc.; Waltham; USA), 
column: Reprosil-Pur Basic HD (150 × 3 mm; 3 µm; Dr. Maisch GmbH; Ammerbuch; 
Germany), gradient: 10-90-10% MeCN/20 mM NH4OAcaq. (v/v, 15 min, 0.6 mL/min]. 1H, 13C 
and 19F-NMR spectra were recorded on VARIAN Mercury plus (300 MHz for 1H-NMR, 75 MHz 
for 13C-NMR, 282 MHz for 19F-NMR) and BRUKER DRX-400 (400 MHz for 1H-NMR, 100 MHz 
for 13C-NMR, 377 MHz for 19F-NMR); chemical shifts (δ) in parts per million (ppm) are related 
to internal standard tetramethylsilane and coupling constants (J). High resolution mass spectra 
(HRMS) were recorded on a FT-ICR APEX II spectrometer (Bruker Daltonics; Bruker 
Corporation; Billerica; USA) using electrospray ionization (ESI).  
General procedure A 
A solution of the corresponding fluoro-methylpyridine (100 mg, 1 eq, 0.90 mmol) in CCl4 (2 mL) 
was treated with NBS (168 mg, 1.05 eq, 0.95 mmol) and AIBN (44 mg, 0.3 eq, 0.27 mmol) and 
stirred overnight at 80 °C. After filtration of the reaction mixture, the solvent was removed by 
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rotary evaporation. The remaining residue was dissolved in EA (20 mL) and the organic phase 
was washed with water (3 x 20 mL) and brine (20 mL), dried over anhydrous Na2SO4, filtered 
and evaporated to dryness. The crude product was purified by flash chromatography (silica, 
gradient ethyl acetate / petroleum ether (EA/PE1:8 → 1:7 → 1:6) to give the corresponding 
bromomethyl-fluoropyridine (3a-d) as colorless oil.  
5-(bromomethyl)-2-fluoropyridine (3a). General procedure A; colorless oil; 54% yield; TLC 
(EA/PE, 1:6): Rf = 0.35; 1H-NMR (400 MHz, CDCl3): δ = 8.23 (d, J = 2.6 Hz, 1H), 7.84 (td, J = 
2.6, 7.9 Hz, 1H), 6.93 (dd, J = 3.0, 8.4 Hz, 1H), 4.46 (s, 2H); 13C-NMR (101 MHz, CDCl3): δ = 
163.23 (d, J = 241.0 Hz), 147.61 (d, J = 15.3 Hz), 141.96 (d, J = 8.4 Hz), 131.54 (d, J = 4.7 Hz), 
109.90 (d, J = 37.8 Hz), 28.38 (d, J = 1.8 Hz); according to US9499537B2.1 
3-(bromomethyl)-2-fluoropyridine (3b). General procedure A; colorless oil; 40% yield; TLC 
(EA/PE, 1:6): Rf = 0.35; 1H-NMR (400 MHz, CDCl3): δ = 8.17 (d, J = 5.0 Hz, 1H), 7.83 (ddd, J 
= 2.0, 7.4, 9.6 Hz, 1H), 7.20 (ddd, J = 1.7, 4.9, 7.0 Hz, 1H), 4.47 (s, 2H); 13C-NMR (101 MHz, 
CDCl3): δ = 161.18 (d, J = 241.4 Hz), 147.92 (d, J = 14.8 Hz), 141.67 (d, J = 4.2 Hz), 121.98 
(d, J 4.5 Hz), 120.41 (d, J = 29.6 Hz), 24.68 (d, J = 1.9 Hz); according to US9499537B2.1 
4-(bromomethyl)-2-fluoropyridine (3c). General procedure A; colorless oil; 30 % yield; TLC 
(EA/PE, 1:6): Rf = 0.35; 1H-NMR (400 MHz, CDCl3): δ = 8.19 (d, J = 5.2 Hz, 1H), 7.18 (d, J = 
5.2 Hz, 1H), 6.94 (s, 0H), 4.38 (s, 2H); .19 (dd, J = 0.8, 5.2 Hz, 1H), 7.22 – 7.06 (m, 1H), 6.94 
(tt, J = 0.6, 1.5 Hz, 1H), 4.38 (s, 2H); 13C-NMR (75 MHz, CDCl3): δ = 164.21 (d, J = 239.5 Hz), 
151.91 (d, J = 7.8 Hz), 148.35 (d, J = 15.3 Hz), 121.44 (d, J = 4.2 Hz), 109.60 (d, J = 38.6 Hz), 
29.36 (d, J = 3.5 Hz); according to US9499537B2.1 
2-(bromomethyl)-6-fluoropyridine (3d). General procedure A; colorless oil; 42% yield; TLC 
(EA/PE, 1:6): Rf = 0.35; 1H-NMR (400 MHz, CDCl3): δ = 7.79 (td, J = 7.4, 8.1 Hz, 1H), 7.32 
(dd, J = 2.2, 7.4 Hz, 1H), 6.86 (dd, J = 2.7, 8.2 Hz, 1H), 4.46 (s, 2H); 13C-NMR (101 MHz, 
CDCl3): δ = 162.94 (d, J = 241.3 Hz), 155.61 (d, J = 13.4 Hz), 142.05 (d, J = 7.7 Hz), 120.69 
(d, J = 4.2 Hz), 109.12 (d, J = 36.7 Hz), 32.29; according to Wenzel et al.2 
General procedure B  
To a solution of the corresponding (hetero)arene bromide (2a-c or 3a-d, 1 eq, 0.34 mmol) in 1 
mL DMF was added 6-hydroxy-2,3-dihydro-1H-inden-1-one (1, 50 mg, 1 eq, 0.34 mmol) and 
K2CO3 (3 eq, 1.01 mmol). The reaction mixture was then stirred overnight at room temperature. 
After the addition of 20 mL water, the aqueous phase was extracted with EA (3 x 20 mL) and 
the combined organic phases were washed with brine (20 mL), dried over anhydrous MgSO4, 
filtered and evaporated to dryness. The crude product was purified by flash chromatography 
(silica, gradient EA/PE 1:2 → 1.5:2 → 1:1 for 5-10 or gradient DCM/MeOH 100:0.5 → 100:1→ 
100:1.5 for 11-14) to afford the corresponding fluorinated derivative (5-11) as tan solid. 
6-((4-fluorobenzyl)oxy)-2,3-dihydro-1H-inden-1-one (5). General procedure B; tan solid; 79% 
yield; TLC (EA/PE, 1:1): Rf = 0.66; M. p. = 77 °C; LC-MS: tR = 11.2 min, > 99%; 1H-NMR (400 
MHz, CDCl3): δ = 7.48 – 7.35 (m, 3H), 7.31 – 7.23 (m, 2H), 7.14 – 7.03 (m, 2H), 5.07 (s, 2H), 
3.12 – 3.06 (m, 2H), 2.77 – 2.69 (m, 2H); 19F-NMR (377 MHz, CDCl3): δ = -113.96; 13C-NMR 
(101 MHz, CDCl3): δ = 207.02, 162.72 (d, J = 246.5 Hz), 158.43, 148.47, 138.40, 132.36, 
129.58, 129.50, 127.67, 124.70, 115.81, 115.60, 106.25, 69.76, 37.13, 25.28; HRFT-MS 
(ESI+): m/z = 279.0794 (calcd. 279.0792 for [M+H]+). 
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6-((3-fluorobenzyl)oxy)-2,3-dihydro-1H-inden-1-one (6). General procedure B; tan solid; 74% 
yield; TLC (EA/PE, 1:1): Rf = 0.66; M. p. = 103 °C; LC-MS: tR = 11.4 min, > 99; 1H-NMR (400 
MHz, CDCl3): δ = 7.41 (dd, J = 0.9, 8.2 Hz, 1H), 7.37 (td, J = 5.9, 8.0 Hz, 1H), 7.33 – 7.24 (m, 
2H), 7.24 – 7.20 (m, 1H), 7.17 (dt, J = 2.1, 9.7 Hz, 1H), 7.08 – 6.96 (m, 1H), 5.11 (s, 2H), 3.15 
– 3.05 (m, 2H), 2.79 – 2.67 (m, 2H); 19F-NMR (377 MHz, CDCl3): δ = -112.67; 13C-NMR (101 
MHz, CDCl3): δ = 206.87, 163.01 (d, J = 246.4 Hz), 158.19, 148.43, 139.06 (d, J = 7.4 Hz), 
138.29, 130.21 (d, J = 8.3 Hz), 127.59, 124.52, 122.76 (d, J = 3.0 Hz), 114.97 (d, J = 21.2 Hz), 
114.23 (d, J = 22.1 Hz), 106.13, 69.43, 37.00, 25.15; ; HRFT-MS (ESI+): m/z = 279.0794 
(calcd. 279.0792 for [M+H]+). 
6-((2-fluorobenzyl)oxy)-2,3-dihydro-1H-inden-1-one (7). General procedure B; tan solid; 72% 
yield; TLC (EA/PE, 1:1): Rf = 0.66; M. p. = 130 °C; LC-MS: tR = 11.3 min, > 99%; 1H-NMR (400 
MHz, CDCl3): δ = 7.51 (td, J = 1.8, 7.5 Hz, 1H), 7.41 (d, J = 8.3 Hz, 1H), 7.38 – 7.26 (m, 3H), 
7.19 (td, J = 1.2, 7.5 Hz, 1H), 7.12 (ddd, J = 1.2, 8.3, 9.6 Hz, 1H), 5.18 (s, 2H), 3.13 – 3.03 (m, 
2H), 2.79 – 2.64 (m, 2H); 19F-NMR (377 MHz, CDCl3): δ = -118.39; 13C-NMR (101 MHz, CDCl3): 
δ = 206.99, 160.67 (d, J = 247.5 Hz), 158.42, 148.49, 138.40, 130.03 (d, J = 8.2 Hz), 129.81 
(d, J = 3.9 Hz), 127.64, 124.53, 124.38 (d, J = 3.6 Hz), 123.78 (d, J = 14.3 Hz), 115.58 (d, J = 
21.0 Hz), 106.39, 64.28, 37.12, 25.26; HRFT-MS (ESI+): m/z = 279.0790 (calcd. 279.0792 for 
[M+H]+). 
6-((6-fluoropyridin-3-yl)methoxy)-2,3-dihydro-1H-inden-1-one (8). General procedure B; tan 
solid; 62% yield; TLC (DCM/MeOH, 9:1): Rf = 0.80; M. p. = 113 °C; LC-MS: tR = 10.1 min, > 
97 %; 1H-NMR (400 MHz, CDCl3): δ = 8.30 (s, 1H), 7.89 (td, J = 2.4, 8.0 Hz, 1H), 7.41 (d, J = 
8.1 Hz, 1H), 7.31 – 7.20 (m, 1H), 6.98 (dd, J = 2.8, 8.7 Hz, 1H), 5.08 (s, 2H), 3.17 – 3.04 (m, 
2H), 2.85 – 2.67 (m, 2H); 19F-NMR (377 MHz, CDCl3): δ = -68.41; 13C-NMR (101 MHz, CDCl3): 
δ = 206.75, 163.49 (d, J = 240.0 Hz), 157.92, 148.70, 146.91 (d, J = 15.2 Hz), 140.78 (d, J = 
8.2 Hz), 138.34, 129.85, 127.73, 124.43, 109.68 (d, J = 37.5 Hz), 106.07, 67.05, 36.98, 25.17; 
HRFT-MS (ESI+): m/z = 280.0772 (calcd. 280.0744 for [M+H]+). 
6-((2-fluoropyridin-4-yl)methoxy)-2,3-dihydro-1H-inden-1-one (9). General procedure B; tan 
solid; 89 % yield; TLC (DCM/MeOH, 9:1): Rf = 0.85; M. p. = 133 °C; LC-MS: tR = 11.3 min, > 
96%; 1H-NMR (400 MHz, CDCl3): δ = δ 8.23 (s, 1H), 7.42 (d, J = 8.4 Hz, 1H), 7.28 (dd, J = 2.6, 
8.4 Hz, 1H), 7.22 (d, J = 5.0 Hz, 1H), 7.20 (d, J = 2.6 Hz, 1H), 7.03 (s, 1H), 5.14 (s, 2H), 3.22 
– 2.96 (m, 2H), 2.82 – 2.61 (m, 2H); 19F-NMR (377 MHz, CDCl3): δ = -67.27; 13C-NMR 
(101 MHz, CDCl3): δ = 206.80, 164.25 (d, J = 239.0 Hz), 157.73, 151.80 (d, J = 7.8 Hz), 149.00, 
148.05 (d, J = 13.9 Hz), 138.50, 127.97, 124.44, 119.19, 107.39 (d, J = 40.2 Hz), 106.15, 
67.95, 37.09, 25.30; HRFT-MS (ESI+): m/z = 280.0790 (calcd. 280.0744 for [M+H]+).  
6-((2-fluoropyridin-3-yl)methoxy)-2,3-dihydro-1H-inden-1-one (10). General procedure B; tan 
solid; 66% yield; TLC (DCM/MeOH, 9:1): Rf = 0.80; M. p. = 138 °C; LC-MS: tR = 10.1 min, > 
99 %; 1H-NMR (400 MHz, CDCl3): δ = 8.22 (s, 1H), 8.01 – 7.90 (m, 1H), 7.41 (dq, J = 1.1, 7.8 
Hz, 1H), 7.32 – 7.18 (m, 3H), 5.14 (s, 2H), 3.16 – 2.92 (m, 2H), 2.83 – 2.60 (m, 2H); 19F-NMR 
(377 MHz, CDCl3): δ = -71.67; 13C-NMR (101 MHz, CDCl3): δ = 206.72, 160.86 (d, J = 239.4 
Hz), 157.89, 148.69, 147.07 (d, J = 6.7 Hz), 139.77 (d, J = 4.4 Hz), 138.39, 127.72, 124.14, 
121.73, 119.01 (d, J = 21.7 Hz), 106.38, 63.69, 36.99, 25.17; HRFT-MS (ESI+): m/z = 280.0773 
(calcd. 280.0744 for [M+H]+). 
6-((6-fluoropyridin-2-yl)methoxy)-2,3-dihydro-1H-inden-1-one (11). General procedure B; tan 
solid; 75% yield; TLC (DCM/MeOH, 9:1): Rf = 0.85; M. p. = 154 °C; LC-MS: tR = 11.3 min, > 
95%; 1H-NMR (400 MHz, CDCl3): δ = 7.80 (q, J = 7.9 Hz, 1H), 7.43 – 7.34 (m, 2H), 7.33 – 7.21 
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(m, 2H), 6.87 (dd, J = 2.7, 8.3 Hz, 1H), 5.14 (s, 2H), 3.14 – 2.97 (m, 2H), 2.79 – 2.63 (m, 2H); 
19F-NMR (377 MHz, CDCl3): δ = -67.14; 13C-NMR (101 MHz, CDCl3): δ = 206.71, 163.09 (d, J 
= 240.7 Hz), 157.91, 155.69 (d, J = 13.0 Hz), 148.50, 141.85 (d, J = 7.8 Hz), 138.36, 127.64, 
123.96, 118.38, 108.57 (d, J = 36.6 Hz), 106.66, 70.01, 36.99, 25.14; HRFT-MS (ESI+): m/z = 
280.0771 (calcd. 280.0744 for [M+H]+). 
General procedure C  
The corresponding benzoic acid (4a-d, 1.1 eq, 0.37 mmol), HATU (1.3eq, 0.44 mmol) and 
triethylamine (3 eq, 1.01 mmol) were dissolved in DCM (3 mL) and stirred at room temperature 
for 30 min. After the addition of the 6-hydroxy-2,3-dihydro-1H-inden-1-one (1, 50 mg, 1 eq, 
0.34 mmol), the reaction mixture was stirred overnight at room temperature. The solvent was 
removed by rotatory evaporation and the remaining residue was dissolved in EA (10 mL). After 
the addition of 50 mL NaHCO3, the aqueous phase was extracted with EA (3 x 20 mL) and the 
combined organic phases were washed with brine (20 mL), dried over anhydrous Na2SO4, 
filtered and evaporated to dryness. The crude product was purified by flash chromatography 
(silica, gradient EA/PE 1:2 → 1.5:2 → 1:1) to afford the corresponding fluorinated derivative (12-
15) as tan solid. 
3-oxo-2,3-dihydro-1H-inden-5-yl 6-fluoronicotinate (12). General procedure C; tan solid; 23 % 
yield; TLC (EA/PE, 1:2): Rf = 0.45; M. p. = 125 °C; LC-MS: tR = 10.1 min, > 96%; 1H-NMR (300 
MHz, CDCl3): δ = 9.06 (dt, J = 2.6, 0.8 Hz, 1H), 8.55 (ddd, J = 8.6, 7.4, 2.4 Hz, 1H), 7.59 (dq, 
J = 2.4, 0.6 Hz, 1H), 7.56 (dq, J = 8.3, 0.8 Hz, 1H), 7.44 (dd, J = 8.3, 2.3 Hz, 1H), 7.10 (ddd, J 
= 8.6, 2.9, 0.7 Hz, 1H), 3.23 – 3.13 (m, 2H), 2.82 – 2.72 (m, 2H); 19F-NMR (282 MHz, CDCl3): 
δ = -59.61; 13C-NMR (101 MHz, CDCl3): δ = 205.73, 166.31 (d, J = 247.2 Hz), 162.78, 152.79, 
151.09 (d, J = 16.9 Hz), 149.81, 143.15 (d, J = 9.6 Hz), 138.57, 128.12, 127.79, 123.63 (d, J 
= 4.6 Hz), 116.42, 109.96 (d, J = 37.5 Hz), 36.88, 25.54; HRFT-MS (ESI+): m/z = 272.0729 
(calcd. 272.0717 for [M+Na]+). 
3-oxo-2,3-dihydro-1H-inden-5-yl 2-fluoroisonicotinate (13). General procedure C; tan solid; 
76% yield; TLC (EA/PE, 1:2): Rf = 0.45; M. p. = 130 °C; LC-MS: tR = 10.2 min, > 97%; 1H-NMR 
(300 MHz, CDCl3): δ = 8.46 (dt, J = 5.1, 0.8 Hz, 1H), 7.90 (dddd, J = 5.2, 1.7, 1.3, 0.5 Hz, 1H), 
7.66 (ddt, J = 2.5, 1.3, 0.6 Hz, 1H), 7.63 – 7.48 (m, 2H), 7.44 (ddd, J = 8.2, 2.3, 0.5 Hz, 1H), 
3.24 – 3.14 (m, 2H), 2.83 – 2.73 (m, 2H); 19F-NMR (282 MHz, CDCl3): δ = -65.48; 13C-NMR 
(101 MHz, CDCl3): δ = 205.62, 164.28 (d, J = 240.8 Hz), 162.42 (d, J = 4.2 Hz), 152.98, 149.72, 
149.05 (d, J = 14.5 Hz), 141.81 (d, J = 7.8 Hz), 138.63, 127.90, 127.84, 121.11 (d, J = 4.8 Hz), 
116.24, 110.33 (d, J = 39.5 Hz), 36.87, 25.55; HRFT-MS (ESI+): m/z = 272.0725 (calcd. 
272.0717 for [M+H]+). 
3-oxo-2,3-dihydro-1H-inden-5-yl 2-fluoronicotinate (14). General procedure C; tan solid; 92% 
yield; TLC (EA/PE, 1:2): Rf = 0.26; M. p. = 163 °C; LC-MS: tR = 9.8 min, > 98%; 1H-NMR (300 
MHz, CDCl3): δ = 8.60 – 8.50 (m, 1H), 8.48 (ddt, J = 4.8, 2.0, 0.9 Hz, 1H), 7.64 – 7.50 (m, 2H), 
7.45 (dd, J = 8.2, 2.3 Hz, 1H), 7.42 – 7.33 (m, 1H), 3.23 – 3.13 (m, 2H), 2.82 – 2.72 (m, 2H); 
19F-NMR (282 MHz, CDCl3): δ = -60.39 (d, J = 9.0 Hz); 13C-NMR (101 MHz, CDCl3): δ = 205.75, 
161.79 (d, J = 250.9 Hz), 161.61 (d, J = 8.6 Hz), 152.79, 152.59 (d, J = 15.6 Hz), 149.80, 
143.66, 138.52, 128.13, 127.75, 121.68 (d, J = 5.0 Hz), 116.38, 113.00 (d, J = 24.5 Hz), 36.88, 
25.53; HRFT-MS (ESI+): m/z = 272.0737 (calcd. 272.0717 for [M+H]+). 
3-oxo-2,3-dihydro-1H-inden-5-yl 6-fluoropicolinate (15). General procedure C; tan solid; 61% 
yield; TLC (EA/PE, 1:2): Rf = 0.26; M. p. = 157 °C; LC-MS: tR = 9.7 min, > 97%; 1H-NMR (300 
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MHz, CDCl3): δ = 8.18 (ddd, J = 7.4, 2.1, 0.8 Hz, 1H), 8.04 (dt, J = 8.2, 7.5 Hz, 1H), 7.62 – 
7.59 (m, 1H), 7.54 (dq, J = 8.2, 0.8 Hz, 1H), 7.45 (dd, J = 8.2, 2.3 Hz, 1H), 7.29 – 7.20 (m, 1H), 
3.22 – 3.12 (m, 2H), 2.81 – 2.72 (m, 2H); 19F-NMR (282 MHz, CDCl3): δ = -64.10 (d, J = 8.2 
Hz); 13C-NMR (101 MHz, CDCl3): δ = 205.79, 163.04 (d, J = 244.0 Hz), 162.60, 152.79, 150.17, 
145.37 (d, J = 12.8 Hz), 142.35 (d, J = 7.6 Hz), 138.51, 128.23, 127.74, 123.60 (d, J = 3.9 Hz), 
116.50, 114.76 (d, J = 36.8 Hz), 36.88, 25.53; HRFT-MS (ESI+): m/z = 272.0733 (calcd. 
272.0717 for [M+H]+). 
Precursor synthesis 
To a solution of 2-(3-(bromomethyl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (16, 
220 mg, 1.1 eq, 0.74 mmol) in 2 mL DMF were added 6-hydroxy-2,3-dihydro-1H-inden-1-one 
(1, 50 mg, 1 eq, 0.67 mmol) and potassium carbonate (280 mg, 3 eq, 2.02 mmol). The reaction 
mixture was then stirred overnight at room temperature. After filtration and washing with 
ethanol, the crude product was purified by flash chromatography (silica, gradient EA/PE 1:6 → 
1:5 → 1:4 → 1:3 → 1:2) to afford the boronic acid pinacol ester 17 as a tan solid. 
6-((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)oxy)-2,3-dihydro-1H-inden-1-one 
(17). 45% yield; TLC (EA/PE, 1:1): Rf = 0.69; 1H-NMR (300 MHz, CDCl3): δ = 7.88 (tt, J = 0.7, 
1.3 Hz, 1H), 7.78 (dt, J = 1.3, 7.3 Hz, 1H), 7.53 (dtd, J = 0.7, 1.4, 7.7 Hz, 1H), 7.41 – 7.34 (m, 
2H), 7.28 (d, J = 1.5 Hz, 1H), 5.07 (s, 2H), 3.18 – 3.03 (m, 2H), 2.78 – 2.67 (m, 2H), 1.36 (s, 
12H); 13C-NMR (75 MHz, CDCl3): δ = 207.09, 158.69, 148.31, 138.37, 135.82, 134.76, 134.22, 
134.18, 130.75, 128.20, 127.56, 124.73, 106.27, 84.06, 70.49, 37.13, 25.26, 25.01. 
Binding affinities 
The binding affinities of the synthesized compounds towards MAO-B were determined in 
radioligand competition binding assays developed in-house.3 The assays were performed 
using rat brain membrane homogenates and the MAO-B specific radioligand L-[3H]deprenyl 
(Novandi Chemistry AB, NT1063, Södertälje, Sweden). Membrane suspension was incubated 
with 2 nM L-[3H]deprenyl and various concentrations (10-12-10-5 M) of the test compound in 50 
mM tris(hydroxymethyl)aminomethane–HCl (Tris−HCl), pH 7.4 buffer containing 120 mM 
NaCl, 5 mM KCl, 2 mM MgCl2, at room temperature for 60 min. Non-specific binding was 
determined in the presence of 10 μM of rasagiline. The reaction was terminated by rapid 
filtration using Whatman GF/B glass-fibre filters, pre-soaked in 0.3% polyethyleneimine, and a 
48-channel harvester (Biomedical Research and Development Laboratories, Gaithersburg, 
MD, USA) followed by washing four times with ice-cold TRIS-HCl buffer. Filter-bound 
radioactivity was quantified by liquid scintillation counting. At least four separate experiments 
in triplicate were performed for determination of Ki values. The data was analysed with 
GraphPad Prism, version 4.1 (GraphPad Inc., La Jolla, CA) according to the Cheng-Prusoff 
equation. For the most potent compounds (6, 9 and 13) the binding affinities towards the MAO-
A isoform and the histamine H3 receptor (H3R) were determined by Cerep (France, Item 443 
and Item1332, respectively). The selected compounds were tested at a concentration of 
100 nM. The MAO-A assay was performed with [3H]Ro 41-1049 on rat brain homogenates and 
the human H3R GPCR binding with [3H]N-alpha-Me-histamine. 
Manual radiosynthesis of [18F]6  
No-carrier-added (n.c.a.) [18F]fluoride was produced via the 18O(p,n)18F nuclear reaction by 
irradiation of a [18O]H2O target (Hyox 18 enriched water; Rotem Industries Ltd, Mishor Yamin, 
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Israel) on a Cyclone®18/9 (IBA RadioPharma Solutions, Louvain-la-Neuve, Belgium) with 18 
MeV proton beam using a Nirta® [18F]fluoride XL target or [18O]H2O recycled by the established 
in-house method4 Starting with 1–2 GBq of n.c.a. [18F]fluoride, [18F]F−-containing anion resin 
[Sep-Pak® Accell Plus QMA Carbonate Plus light cartridge (Waters GmbH, Eschborn, 
Germany)] was eluted with a solution composed of 100 L of tetra-n-butylammonium hydrogen 
carbonate (TBAHCO3, 0.075 M, ABX advanced biochemical compounds GmbH, Radeberg, 
Germany) and K2CO3 (20 mg/mL solution, 0.6 mg, 4.3 mol) in H2O/MeCN (1:4, v/v) in a total 
volume of 1.2 mL. The solution was transferred directly into a 5 mL microwave V-vial (CEM® 
Corporation, Matthews, NC, USA) and azeotropically dried under vacuum and argon flow in 
the microwave cavity (Discover PETwave microwave CEM® corporation, 50–60 °C, 75 W) for 
8–10 min. Additional aliquots of MeCN (2 × 1.0 mL) were added during the drying process. 
After complete dryness, a solution containing the pinacol ester precursor 17 (3 mg, 8.2 mol) 
and tetrakis(pyridine)copper(II) triflate [Cu(py)4(OTf)2] ( 10 mg, 15 mol) in N,N-
dimethylacetamide (DMA, 600 L) and tert-BuOH (300 L) was added to the reactive 
anhydrous [18F]TBAF. The reaction was monitored in different time points (up to 15 min) at 
110°C via radio-thin layer chromatography (radio-TLC) and high performance liquid 
chromatography (HPLC, see quality control section). After the completion of the reaction, the 
crude reaction mixture was diluted with 18 mL H2O and passed through a Sep-Pak® C18 Plus 
cartridge (Waters GmbH, Eschborn, Germany) to remove the excess of Cu(py)4(OTf)2 and 
some UV impurities. The cartridge was then eluted with 2.5 mL of MeCN and further diluted 
with 2.5 mL of H2O. This solution was directly applied onto a semi-preparative HPLC system 
composed by a Reprosil-Pur C18-AQ column (Dr. Maisch HPLC GmbH, Germany) with an 
eluent of 58% MeCN/20 mM NH4OAcaq. at a flow rate of 3.8 mL∙min-1. [18F]6 was collected and 
diluted in 40 mL of H2O. Final purification was performed using a Sep-Pak® C18 Light cartridge 
(Waters, Milford, MA, USA) followed by elution with 1.2 mL of EtOH. To obtain an injectable 
solution, the solvent was concentrated under a gentle nitrogen stream at 70 °C and [18F]6 was 
formulated in a sterile isotonic saline solution (5–10% EtOH, v/v). The identity of [18F]6 was 
verified by radio-HPLC analysis of an aliquot of the radiotracer solution co-injected with the 
corresponding reference compound 6. Radiochemical and chemical purities were assessed by 
radio-TLC and analytical HPLC. Molar activities were determined based on aliquots taken from 
the formulation, and the mass determination for the corresponding reference standard was 
performed via a calibration curve obtained under the same analytical HPLC conditions (see 
quality control section).  
Automated radiosynthesis of [18F]6  
Remote controlled radiosynthesis was performed using a Synchrom R&D EVO III automated 
synthesizer (Elysia-Raytest, Germany). The setup of the automat is depicted in the 
supplemental information (Figure S2) and the reagents and conditions used as described for 
the manual synthesis. Briefly, [18F]fluoride (4-6 GBq) was trapped on a Waters QMA cartridge 
(Trap 1) and eluted with a solution (vial SC1) containing 100 L of TBAHCO3 and 30 L K2CO3 
dissolved in a mixture of H2O/MeCN (1:4, v/v) into the reaction vessel and dried via azeotropic 
distillation. Additional 1.5 mL of dried MeCN was added (vial SC2). After complete dryness, a 
solution containing 8.2 mol of boronic acid pinacol ester 17 and 15 mol Cu(py)4(OTf)2 in 
DMA/tert-BuOH (2:1, v/v, vial SC3) was added, and the reaction mixture was stirred at 120 °C 
for 10 min. To remove the excess of copper catalyst and some UV impurities a C18 light 
cartridge (Trap 2) was applied prior to the semi-preparative HPLC isolation of [18F]6. For that 
purpose, the reaction mixture was diluted with 18 mL H2O (vial SC4) and the cartridge eluted 
9 
 
with 2.5 mL MeCN (vial SC5). After further dilution with 2.5 mL H2O (vial SC7), the solution 
was transferred to the semi-preparative HPLC. [18F]6 was collected in the HPLC collection vial 
containing 40 mL of H2O and trapped in the Sep-Pak C18 light cartridge (Trap 4). The 
cartridge was washed with 2 mL H2O (vial SC10), and [18F]6 eluted with 1.3 mL EtOH (vial 
SC11). The ethanolic solution containing [18F]6 was transferred outside of the hotcell, the 
solvent was evaporated at 70 °C in a gentle stream of nitrogen for 5-10 min, and [18F]6 was 
reconstituted in a saline solution (0.9 % NaCl). [18F]6 was then ready for further biological 
characterization in a total synthesis time of about 60 min.  
Quality control  
Radio-thin layer chromatography (radio-TLC) of [18F]6 was performed on Alugram® SIL 
G/UV254 pre-coated plates (Macherey-Nagel; Düren; Germany) with PE:EA (1:1, v/v). The 
plates were exposed to storage phosphor screens (BAS IP MS 2025 E, GE Healthcare Europe 
GmbH, Freiburg, Germany) and recorded using the Amersham Typhoon RGB Biomolecular 
Imager (GE Healthcare Life Sciences). Images were quantified with the ImageQuant TL8.1 
software (GE Healthcare Life Sciences). Analytical chromatographic separations were 
performed on a JASCO LC-2000 system, incorporating a PU-2080Plus pump, AS-2055Plus 
auto injector (100 L sample loop), and a UV-2070Plus detector coupled with a gamma 
radioactivity HPLC flow detector (Gabi Star, Raytest Isotopenmessgeräte GmbH). Data 
analysis was performed with the Galaxie chromatography software (Agilent Technologies, 
USA) using the chromatograms obtained at 254 nm. Radiochemical yield from aliquots of the 
reaction mixture, radiochemical purities and in vivo metabolism analysis of plasma and brain 
samples were assessed via reverse phase – high performance liquid chromatography (RP-
HPLC) in gradient mode (0–10 min: 10% MeCN/20 mM NH4OAcaq., 10–30 min: 10%→90% 
MeCN/20 mM NH4OAcaq., 30–35 min: 90% MeCN/20 mM NH4OAcaq., 35–36 min: 90%→10% 
MeCN/20 mM NH4OAcaq. 36–45 min: 10% MeCN/20 mM NH4OAcaq.). The molar activity was 
determined using analytical radio-HPLC with a Reprosil-Pur C18-AQ column (250 × 4.6 mm, 
5 μm) and 54% MeCN/20 mM NH4OAcaq. as eluent at a flow rate of 1 mL·min−1 obtained at 254 
nm.  
Determination of in vitro stability and lipophilicity (LogD7.4) 
In vitro radiochemical stability of [18F]6 was investigated in 0.9% NaCl solution, PBS (pH 7.2) 
at 40 °C and in EtOH at room temperature for up to 90 min. Samples were taken at 30 min and 
90 min of incubation time and analysed by radio-TLC and radio-HPLC. LogD7.4 of [18F]6 was 
experimentally determined in n-octanol/phosphate-buffered saline (PBS; 0.01 M, pH 7.4) at 
room temperature by the shake-flask method. The measurement was performed twice in 
triplicate. 
Biological evaluation 
All experimental work including animals has been conducted in accordance with the national 
legislation on the use of animals for research [Tierschutzgesetz (TierSchG), Tierschutz-
Versuchstierverordnung (TierSchVersV)] and were approved by the Animal Care and Use 
Committee of Saxony (TVV 18/18; TVV 36/18 Landesdirektion Sachsen). Female CD-1 mice 
and Fischer rats F344 were obtained from the Medizinisch-Experimentelles Zentrum at 




In vitro autoradiography 
Cryosections of brains obtained from female CD1 mice (10–12 weeks old, 25-38 g), SPRD rats 
(10-12 weeks, 250-300 g) and domestic piglets (Sus s. domestica, 6 weeks, 12–14 kg)) were 
thawed, dried in a stream of cold air, and pre-incubated in 50 mM TRIS-HCl buffer (pH 7.4, 
120 mM NaCl, 5 mM KCl, 2 mM MgCl2) 2x5 min at ambient temperature. Afterwards, brain 
sections were incubated with either 10 nM L-[3H]deprenyl or 0.1-0.2 MBq/mL [18F]6 in buffer 
for 60 min at room temperature. Non-specific binding was determined in the presence of 10 µM 
of L-deprenyl, rasagiline or compound 6, respectively. Subsequently, the sections were 
washed 2 x 5 min in ice-cold TRIS-HCl buffer, and dipped for 5 s in ice-cold deionized water. 
The sections were rapidly dried in a stream of cold air before being exposed for three weeks 
or overnight on an imaging plate (Fujifilm Corporation, Tokyo, Japan). Developed 
autoradiographs were analysed in a phosphor imager (HD-CR 35; Duerr NDT GmbH, 
Bietigheim Bissingen, Germany). The quantification was performed by using 2D-densitometric 
analysis (AIDA 2.31 software; Raytest Isotopenmessgeräte GmbH, Germany) and presented 
in intensity/area (QL/pixel).  
PET Scanning Protocol 
For the time of the experiments, female CD-1 mice (n = 3; 10 weeks; 30-35 g) were kept in a 
dedicated climatic chamber with free access to water and food under a 12:12h dark:light cycle 
at a constant temperature (24 °C). The animals were anaesthetized (Anaesthesia Unit U-410, 
agntho’s, Lidingö, Sweden) with isoflurane (1.8%, 0.35 L/min) delivered in a 60% oxygen/40% 
air mixture (Gas Blender 100 Series, MCQ instruments, Rome, Italy) and maintained at 37 °C 
with a thermal bed system. [18F]6 was injected into the tail vein (CD-1 mice; 5.3 ± 2.6 MBq in 
150 µL isotonic saline; Am: 13-20 GBq/µmol, EOS) followed by a 60 min PET/MR scan (Mediso 
nanoScan®, Hungary). Each mouse was used as its own control, undergoing a baseline and 
then the blocking experiment. Blocking studies (n = 3) were performed with an intravenous 
(i.v.) injection of 1 mg/kg L-deprenyl (Tocris Bioscience, Bristol, UK) 10 min prior to injection 
of [18F]6. Each PET image was corrected for random coincidences, dead time, scatter and 
attenuation (AC), based on a whole body (WB) MR scan. The reconstruction parameters for 
the list mode data were 3D-ordered subset expectation maximization (OSEM), 4 iterations, 6 
subsets, energy window: 400-600 keV, coincidence mode: 1-5, ring difference: 81. The mice 
were positioned prone in a special mouse bed (heated up to 37 °C), with the head fixed to a 
mouth piece for the anaesthetic gas supply with isoflurane in 40% air and 60% oxygen. The 
PET data were collected by a continuous WB scan during the entire investigation. Following 
the 60 min PET scan a T1 weighted WB gradient echo sequence (TR/TE: 20/6.4 ms, NEX: 1, 
FA: 25, FOV: 64 x 64 mm, Matrix: 128 x 128, STh: 0.5 mm) was performed for AC and 
anatomical orientation. Image registration and evaluation of the region of interest (ROI) was 
done with PMOD (PMOD Technologies LLC, v. 3.9, Zurich, Switzerland). The respective brain 
regions were identified using the mouse brain atlas template Ma-Benveniste-Mirrione-FDG. 
The activity data is expressed as mean SUV of the overall ROI.  
In vivo metabolite analysis 
From the same animals used in the PET studies, brain and blood samples were obtained at 
30 min p.i., plasma was separated by centrifugation (14,000 × g, 1 min), and brain 
homogenized in ~ 1 mL isotonic saline on ice [10 strokes of a polytetrafluoroethylene (PTFE) 
plunge at 1000 rpm in a borosilicate glass cylinder; Potter S Homogenizer, B. Braun Melsungen 
AG, Melsungen, Germany]. Two consecutive extractions were performed as duplicate for 
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plasma and brain determinations. Plasma and brain samples were added to an ice-cold 
MeOH/H2O mixture (8:2, v/v). The samples were vortexed for 3 min, incubated on ice for 5 min 
and centrifuged at 12,000 rpm for 5 min. Supernatants were collected and the precipitates 
were re-dissolved in 100 µL of extraction solvent and the extracted procedure was repeated. 
The extraction efficiencies were calculated by the ratio of radioactivity in the supernatant by 
the total radioactivity in the sample (precipitate + supernatant) measured in an automated 
gamma counter (1480 WIZARD, Fa. Perkin Elmer). The supernatants from both extractions 
were combined, concentrated at 70 °C under argon stream up to a remaining volume of 100 
µL, and subsequently quantified by analytical radio-HPLC with a gradient system (see quality 
control section).  
In vitro liver microsome studies 
Incubations with MLM and HLM had a final volume of 250 µL and were performed in PBS (pH 
7.4) as follows,5 with final concentrations as stated in brackets. PPS, MLM or HLM (1 mg/mL 
respectively), and [18F]6 (~3 MBq) were mixed vigorously and pre-incubated for 3 min at 37°C. 
Analogously pre-incubated NADPH (2 mM) in PBS was added and mixtures were shaken 
gently at 37 °C. After termination at 15, 30, and 60 min by addition of 250 µL ice-cold MeCN 
and vigorous mixing for 30 s, samples were cooled on ice for 5 min, and centrifuged at 14,000 
rpm for 10 min. Supernatants were immediately analysed by fast radio-HPLC. For each time 
point incubations were performed in duplicate, containing small amounts of EtOH (0.025%), 
resulting from formulation of [18F]6. Extraction efficiencies were determined as described for 
”In vivo metabolite analyses” and accounted for 91.5% (mean, n = 10, SD = 2.2%). Incubations 
without MLM or HLM, and NADPH, respectively, were performed for 60 min as negative 
controls. Similar to the protocol described above positive controls were performed using 
testosterone (20 µM) instead of [18F]6 as substrate, whereby after 90 min complete conversion 
by MLM and HLM was respectively confirmed by RP-HPLC analyses with UV detection. For 
monitoring of metabolic depletion [18F]6 the HPLC system (X-LC, JASCO) with radioactivity 
detection was used as previously described.5 A ReproSil-Pur 120 C18-AQ column, (150 x 3 
mm, 3 µm, incl. 10 x 3 mm pre-column - both Dr. Maisch GmbH) was used as stationary phase. 
At a flow rate of 0.7 mL·min−1 and a column oven temperature of 25 °C, a semi-isocratic elution 
was performed (0–4 min 67.5% MeCN/20 mM NH4OAcaq., 4–5.5 min 90% MeCN/20 mM 
NH4OAcaq, 5.5–9 min 67.5% MeCN/20 mM NH4OAcaq), whereby unchanged [18F]6 eluted at 
3.9 min and radiometabolites in the range of 0.7-4.5 min. For microsome experiments, the 
following instruments were used: a BioShake iQ (QUANTIFOIL Instruments, Jena, Germany) 






Figure S 1: Representative competition binding curves for compounds 5-15. 
 
 
Figure S 2: Representative radio (red line)-  and UV (gray line)- HPLC chromatograms of the 
crude reaction mixtures of [18F]6 co-eluted with the reference compound 6. (A) manual 
synthesis (RCY: 49%) [Reprosil-Pur C18-AQ column (250 x 4.6 mm, 5 µm), 58% MeCN/20 
mM NH4OAc, Flow rate: 1 mL∙min−1] and (B) automated radiosynthesis (RCY: 25%) [Reprosil- 




B 90% ACN/aq. 20 mM NH4OAc; 0–10 min 100% A, 10–30 min up to 100% B, 30–35 min 
100% B, 35-36 min 100% A, 36–45 min 100% A); Flow: 1 mL∙min-1]. 
 
 
Figure S 3: Schematic representation of the setup for the automated radiosynthesis of [18F]6 
using the Synchrom R&D EVO III automated synthesizer (Elysia-Raytest, Germany). 
18F]Fluoride (4-6 GBq) was trapped on a Waters QMA cartridge (Trap 1) and eluted with a 
solution (vial SC1) containing 100 L of TBAHCO3 and 30 L K2CO3 dissolved in a mixture of 
H2O/MeCN (1:4, v/v) into the reaction vessel and dried via azeotropic distillation. Additional 1.5 
mL of dried MeCN was added (vial SC2). After complete dryness, a solution containing 8.2 
mol of boronic acid pinacol ester 17 and 15 mol Cu(py)4(OTf)2  in DMA/t-BUOH (2:1, v/v, vial 
SC3) was added, and the reaction mixture was stirred at 120 °C for 10 min. To remove the 
excess of copper catalyst and some UV impurities a C18 light cartridge (Trap 2) was applied 
prior to semi-preparative the HPLC isolation. For that purpose, the reaction mixture was diluted 
with 18 mL H2O (vial SC4) and the cartridge eluted with 2.5 mL MeCN (vial SC5). After further 
dilution with 2.5 mL H2O (vial SC7), the solution was transferred to the semi-preparative HPLC. 
[18F]6 was collected in the HPLC collection vial containing 40 mL of H2O and trapped in the 
Sep-Pak C18 light cartridge (Trap 4). The cartridge was washed with 2 mL H2O (vial SC10), 




Figure S 4: 1H-NMR of 6-((4-fluorobenzyl)oxy)-2,3-dihydro-1H-inden-1-one (5). 
 





Figure S 6: 13C-NMR of 6-((4-fluorobenzyl)oxy)-2,3-dihydro-1H-inden-1-one (5). 
 
 







Figure S 8: 1H-NMR of 6-((3-fluorobenzyl)oxy)-2,3-dihydro-1H-inden-1-one (6). 
 
 





Figure S 10: 13C-NMR of 6-((3-fluorobenzyl)oxy)-2,3-dihydro-1H-inden-1-one (6). 
 
 





Figure S 12: 1H-NMR of 6-((2-fluorobenzyl)oxy)-2,3-dihydro-1H-inden-1-one (7). 
 





Figure S 34: 13C-NMR of 6-((2-fluorobenzyl)oxy)-2,3-dihydro-1H-inden-1-one (7). 
 
 






Figure S 16: 1H-NMR of 6-((6-fluoropyridin-3-yl)methoxy)-2,3-dihydro-1H-inden-1-one (8). 
 





Figure S 68: 13C-NMR of 6-((6-fluoropyridin-3-yl)methoxy)-2,3-dihydro-1H-inden-1-one (8). 
 
 






Figure S 7: 1H-NMR of 6-((2-fluoropyridin-4-yl)methoxy)-2,3-dihydro-1H-inden-1-one (9). 
 





Figure S 92: 13C-NMR of 6-((2-fluoropyridin-4-yl)methoxy)-2,3-dihydro-1H-inden-1-one (9). 
 
 







Figure S 114: 1H-NMR of 6-((2-fluoropyridin-3-yl)methoxy)-2,3-dihydro-1H-inden-1-one (10). 
 





Figure S 136: 13C-NMR of 6-((2-fluoropyridin-3-yl)methoxy)-2,3-dihydro-1H-inden-1-one (10). 
 
 






Figure S 158: 1H-NMR of 6-((6-fluoropyridin-2-yl)methoxy)-2,3-dihydro-1H-inden-1-one (11). 
 





Figure S 17: 13C-NMR of 6-((6-fluoropyridin-2-yl)methoxy)-2,3-dihydro-1H-inden-1-one (11). 
 
 







Figure S 192: 1H-NMR of 3-oxo-2,3-dihydro-1H-inden-5-yl 6-fluoronicotinate (12). 
 





Figure S 214: 13C-NMR of 3-oxo-2,3-dihydro-1H-inden-5-yl 6-fluoronicotinate (12). 
 
 






Figure S 236: 1H-NMR of 3-oxo-2,3-dihydro-1H-inden-5-yl 2-fluoroisonicotinate (13). 
 





Figure S 25: 13C-NMR of 3-oxo-2,3-dihydro-1H-inden-5-yl 2-fluoroisonicotinate (13). 
 
 






Figure S 27: 1H-NMR of 3-oxo-2,3-dihydro-1H-inden-5-yl 2-fluoronicotinate (14). 
 





Figure S 292: 13C-NMR of 3-oxo-2,3-dihydro-1H-inden-5-yl 2-fluoronicotinate (14). 
 
 






Figure S 314: 1H-NMR of 3-oxo-2,3-dihydro-1H-inden-5-yl 6-fluoropicolinate (15). 
 





Figure S 336: 13C-NMR of 3-oxo-2,3-dihydro-1H-inden-5-yl 6-fluoropicolinate (15). 
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